"Immunogenicity responses were similar between older and younger adults", an AstraZeneca spokesperson said.
What this means is that the company, which is developing Oxford University's vaccine in India, intends to apply for emergency authorization if the data from the United Kingdom trials show promise.
Another potential coronavirus vaccine is moving along, with especially good news for the elderly.
Older patients are the most affected by the coronavirus pandemic, with the vast majority of deaths occurring among those over the age of 60.
This does not necessarily mean the vaccine, being developed alongside the University of Oxford, is safe and effective in older people - but it is promising news, given that the immune system weakens as a person grows older.
They note that although some countries might deploy COVID-19 vaccines on the strength of safety and immunogenicity data alone, the goal of vaccine development is to gain direct evidence of vaccine efficacy in protecting humans against SARS-CoV-2 infection and disease so that manufacture of efficacious vaccines can be selectively upscaled.
The July results, from an earlier trial phase, showed that the vaccine increased levels of both protective neutralizing antibodies and immune T-cells that target the virus.
The findings came from blood tests carried out on a subset of older participants in the vaccine trials.
Full details are expected to be laid out in scientific journals once they have been reviewed by other experts.
The jab is one of the most advanced experimental coronavirus vaccines in the world.
With 1,537,142 cases, Russian Federation has registered the fourth most positive cases in the world - deaths number at 26,409, as per the Johns Hopkins Coronavirus Resource Centre. "National Health Service England has flexible deployment plans to start the vaccination of prioritised cohorts as soon as the vaccines are approved by the regulatory authorities, now not to be coadministered with the influenza vaccination (although clinical trials are exploring coadministration of influenza and COVID-19 vaccines)".
An Emergency Use Listing (EUL) is meant to make a vaccine available globally faster, while a World Health Organization pre-qualification is a global quality tag that ensures vaccines are safe and effective.